Edition:
United States

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,509.15INR
5:22am EST
Change (% chg)

Rs12.90 (+0.86%)
Prev Close
Rs1,496.25
Open
Rs1,498.95
Day's High
Rs1,513.00
Day's Low
Rs1,493.05
Volume
372,811
Avg. Vol
893,336
52-wk High
Rs1,911.90
52-wk Low
Rs1,280.00

LUPN.NS

Chart for LUPN.NS

About

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)

Overall

Beta: -0.02
Market Cap(Mil.): Rs675,460.69
Shares Outstanding(Mil.): 451.44
Dividend: 7.50
Yield (%): 0.50

Financials

  LUPN.NS Industry Sector
P/E (TTM): 23.63 30.00 30.92
EPS (TTM): 63.31 -- --
ROI: 19.27 15.39 14.82
ROE: 25.62 16.57 16.24

BRIEF-Lupin Ltd launches generic MS Contin ER tablets in U.S.

* Says Lupin launches generic MS Contin ER tablets in the US Source text: http://bit.ly/2jKCOYU Further company coverage:

Jan 13 2017

BRIEF-Lupin gets U.S. FDA approval for Topicort cream

* Lupin receives FDA approval for generic Topicort LP Emollient cream, 0.05% and Topicort cream, 0.25%

Jan 11 2017

Bracco, Guerbet looking for partners for Bayer radiology bids: sources

FRANKFURT Italian healthcare group Bracco is working on a potential bid for the radiology supplies unit that Germany's Bayer AG is considering selling, people close to the matter said.

Dec 07 2016

BRIEF-Lupin receives FDA approval for generic Nuvigil tablets

* Lupin Pharmaceuticals Inc shall commence promoting product in US shortly Source text for Eikon: Further company coverage:

Nov 29 2016

BRIEF-Lupin gets tentative approval for generic Epzicom tablets

* Says Lupin receives tentative approval for generic Epzicom tablets Source text: http://bit.ly/2gfIckH Further company coverage:

Nov 23 2016

BRIEF-Lupin Ltd receives FDA approval for analgesic drugs

* Lupin receives FDA approval for hydrocodone bitartrate and acetaminophen tablets Source text: http://bit.ly/2gk6NWI Further company coverage:

Nov 17 2016

UPDATE 1-India's Lupin Q2 profit lags as costs rise

MUMBAI, Nov 9 Lupin Ltd, India's third-largest drugmaker by sales, reported a 57.6 percent jump in quarterly profit on Wednesday, but missed analysts' expectations due to higher research spending.

Nov 09 2016

CORRECTED-India's Lupin Q2 profit lags estimates

MUMBAI, Nov 9 Lupin Ltd, India's third-largest drugmaker by sales, reported a 57.6 percent jump in quarterly profit, but missed analysts' expectations.

Nov 09 2016

BRIEF-Lupin Sept-qtr consol profit up about 58 pct

* Consensus forecast for Sept-quarter consol profit was 7.16 billion rupees

Nov 09 2016

BRIEF-WPC signs agreement with Mandalay resources to buy Lupin gold mine, Ulu gold project

* WPC signs definitive agreement with Mandalay resources to acquire the Lupin gold mine and the Ulu gold project

Nov 01 2016

Earnings vs. Estimates